During the past decade, New England Hematology/Oncology Associates conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "New England Hematology/Oncology Associates" are "Breast Neoplasms" (1 trials), "Lymphoma, Follicular" (1 trials), "Lymphoma, Low-Grade" (1 trials), "Lymphoma, Mixed-Cell, Follicular" (1 trials) and "Lymphoma, Small Cleaved-Cell, Follicular" (1 trials). Many other conditions were trialed in "New England Hematology/Oncology Associates" in a lesser frequency.

Most popular intervention types in "New England Hematology/Oncology Associates" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Letrozole" (1 trials), "Pixantrone (BBR 2778)" (1 trials), "Zoledronic Acid" (1 trials) and "rituximab" (1 trials). Other intervention names were less common.

The vast majority of trials in "New England Hematology/Oncology Associates" are 1 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "New England Hematology/Oncology Associates". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in New England Hematology/Oncology Associates, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in New England Hematology/Oncology Associates, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".